Thomas Huber
CEO
Athebio AG
Athebio provides drug developers with custom-designed DARPins, a type of protein building block, to create targeted therapeutics with improved efficacy and safety. By offering these tailor-made components and expert support, Athebio enables the creation of advanced therapies.
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Developing targeted biotherapeutics with high specificity, efficacy, and safety can be challenging due to limitations in existing protein scaffolds. Traditional antibody technologies may not access all therapeutically relevant targets or provide the desired level of control over biodistribution and stability. This can hinder the development of effective and safe next-generation therapies.
Solution
Athebio provides drug developers with custom-designed Designed Ankyrin Repeat Proteins (DARPins), called Athebodies, that serve as versatile building blocks for creating targeted biotherapeutics. The Athebody platform combines a stable DARPin scaffold with a discovery engine to generate therapeutic candidates with high target affinity and specificity. These DARPins can be easily linked or conjugated to other modalities, enabling the creation of multi-specific biologics with improved developability and manufacturability. Athebio partners with drug developers, offering access to its Athebody DARPin technology to enable innovative biological solutions across a variety of applications, including targeted radioligand therapies, T-cell receptor mimetics, and targeted gene therapies.
Target Audience
Athebio's primary customers are drug developers in the biopharmaceutical industry seeking to create targeted therapeutics with improved efficacy and safety profiles.
Features
- Athebody DARPins are based on a clinically validated DARPin scaffold with over 2500 patients dosed.
- Small protein scaffold (15 kDa) without S-S bridges, offering high solubility and stability.
- Fully modular binding domain enabling multi-specific binding or providing targeting moieties to other modalities.
- Easily linkable at N and C termini enabling dual- & multi-conjugation or protein fusions.
- Exceptional high target specificity and affinity.
- Rapid, simple, and cost-efficient bacterial-based CMC.
- Fully in vitro selection system allowing tight control of target quality.
- High functional library diversity, yielding a diversity of binders to maximize pre-clinical and clinical success.